COOPER COS INC shareholders Q4 2021

COOPER COS INC's ticker is COO and the CUSIP is 216648402. A total of 581 filers reported holding COOPER COS INC in Q4 2021. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.

COOPER COS INC shareholders Q4 2021
Name	Shares	Value	Weighting ↓
WILLNER & HELLER, LLC	928	$383,000	0.51%
Impax Asset Management Group plc	331,258	$138,777,000	0.51%
MARK SHEPTOFF FINANCIAL PLANNING, LLC	2,331	$976,000	0.47%
OPSEU Pension Plan Trust Fund	4,710	$1,997,000	0.45%
Rheos Capital Works Inc.	24,400	$10,222,000	0.45%
HARBOR CAPITAL ADVISORS, INC.	2,869	$1,202,000	0.44%
Silvant Capital Management LLC	5,702	$2,388,000	0.41%
APPLETON GROUP, LLC	929	$389,000	0.39%
Aristotle Atlantic Partners, LLC	16,000	$6,703,000	0.39%
Mirador Capital Partners LP	4,093	$1,715,000	0.36%
Bellevue Group AG	83,319	$34,906,000	0.36%
ALPHASIMPLEX GROUP, LLC	503	$211,000	0.36%
Yorktown Management & Research Co Inc	1,240	$519,000	0.35%
ArrowMark Colorado Holdings LLC	104,293	$43,693,000	0.35%
Vestmark Advisory Solutions, Inc.	14,723	$6,168,000	0.35%
WESTFIELD CAPITAL MANAGEMENT CO LP	136,913	$57,358,000	0.34%
VICTORY CAPITAL MANAGEMENT INC	879,658	$368,524,000	0.34%
JANUS HENDERSON GROUP PLC	1,929,824	$808,505,000	0.34%
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P.	73,449	$30,772,000	0.32%
FIL Ltd	687,967	$288,217,000	0.30%

About COOPER COS INC

Cooper Cos Inc is a global medical device company that specializes in the manufacturing and distribution of contact lenses, surgical instruments, and diagnostic products. The company has been in operation for over 60 years and has a strong reputation for innovation and quality.

Cooper Cos Inc has a diverse portfolio of products that cater to the needs of various healthcare professionals and patients. The company's contact lens division, CooperVision, is a leading provider of soft contact lenses and has a presence in over 100 countries. The surgical division, CooperSurgical, offers a range of products for gynecologists, obstetricians, and fertility specialists. The diagnostic division, CooperGenomics, provides genetic testing services for reproductive health and oncology.

The company's financial performance has been impressive in recent years, with revenue growth of 7% in 2020. The COVID-19 pandemic had a minimal impact on the company's operations, and it continued to invest in research and development to drive innovation.

Cooper Cos Inc has a strong leadership team, with Al White serving as the CEO and President. The company's board of directors includes experienced professionals from various industries, including healthcare, finance, and technology.

In conclusion, Cooper Cos Inc is a well-established medical device company with a diverse portfolio of products and a strong reputation for innovation and quality. The company's financial performance has been impressive, and it has a strong leadership team in place to drive future growth.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists COOPER COS INC's shareholders in Q4 2021. To view COOPER COS INC's shareholder history, click here.